Skip to content
Clinical Trials – home

Austria Clinical trials in Austria – page 16

  • 520 / 1 111 trials open to patients
  • 30 research sites
  • 47 cities
City
Type of trial
Recruitment status
Quick filters

1 111 trials in Austria

Open in trial search

Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Comparing brincidofovir and cidofovir for treating adenovirus infection in children and adults after stem cell transplantation

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Cidofovir
  • Sponsor:Symbio Pharmaceuticals Ltd.

Glioblastoma

Recruiting

Study of iodofalan (131I) and lomustine combination therapy compared to lomustine alone in patients with first recurrent glioblastoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Telix Pharmaceuticals (Innovations) Pty Limited

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Insel Gruppe AG

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:XELAFASLATIDE
  • Sponsor:ONL Therapeutics Inc.

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:ECRI-trials B.V.

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:ETOP IBCSG Partners Foundation

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bicara Therapeutics Inc.

Top 10 cities in Austria

Where most of the country's trials are run

No. 1 most studied

Vienna

838trials · 32% of the top 10
research sites
10
View city
32%Vienna

Shares are of these cities' trials together.

All cities with clinical trials

47 cities, A–Z – pick yours to filter the trials

Clinical research in Austria

What the registry says about research in the country

01 Oncology and Hematological Malignancies

Austria conducts extensive research in oncology, focusing on a wide range of solid tumors and hematological malignancies. Clinical trials investigate novel therapies for non-small cell lung cancer, breast cancer, colorectal cancer, and prostate cancer, among others. Studies evaluate targeted therapies, immunotherapies, and combination regimens aimed at improving patient outcomes and survival rates.

  • Advanced and metastatic solid tumors including lung, breast, colorectal, and gastric cancers
  • Hematological conditions such as multiple myeloma, acute myeloid leukemia, and lymphomas
  • Novel immunotherapies and targeted agents for various cancer types
  • Combination treatment strategies and personalized medicine approaches

Research in hematological malignancies includes trials on acute lymphoblastic leukemia, chronic lymphocytic leukemia, and myelodysplastic syndromes. These studies explore innovative treatment regimens, including CAR T-cell therapies and novel drug combinations, to enhance disease control and quality of life for patients.

02 Cardiovascular Disease Research

Clinical trials in Austria address a broad spectrum of cardiovascular diseases, including heart failure, coronary artery disease, and hypertension. Research efforts focus on evaluating new pharmacological interventions, device-based therapies, and strategies to reduce cardiovascular events and improve cardiac function in patients with various heart conditions.

  • Heart failure with reduced and preserved ejection fraction
  • Acute coronary syndromes and myocardial infarction
  • Hypertrophic cardiomyopathy and valvular heart disease
  • Prevention of stroke and thromboembolism in atrial fibrillation

Studies also investigate transthyretin amyloid cardiomyopathy and other rare cardiac conditions. Trials aim to assess the efficacy of novel therapeutics in preserving heart function, reducing hospitalizations, and improving long-term outcomes for patients with complex cardiovascular disorders.

03 Immunology and Autoimmune Disorders

Austrian research institutions participate in trials targeting autoimmune diseases and immune system disorders. These studies focus on conditions such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and multiple sclerosis. Investigators evaluate biologics, small molecules, and immunomodulatory therapies to control disease activity and prevent organ damage.

  • Rheumatoid arthritis and other inflammatory joint diseases
  • Systemic lupus erythematosus and lupus nephritis
  • Crohn's disease and ulcerative colitis
  • Multiple sclerosis and neuromyelitis optica

Research also encompasses myasthenia gravis, Sjögren's syndrome, and systemic sclerosis. Clinical trials aim to identify effective treatments that reduce symptoms, improve quality of life, and modify disease progression in patients with chronic autoimmune conditions.

04 Respiratory and Pulmonary Diseases

Trials in Austria investigate therapies for chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis. Studies evaluate bronchodilators, anti-inflammatory agents, and antifibrotic drugs to improve lung function, reduce exacerbations, and slow disease progression in patients with chronic respiratory conditions.

  • Severe eosinophilic asthma and chronic obstructive pulmonary disease
  • Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
  • Pulmonary arterial hypertension and pulmonary vascular disease
  • Cystic fibrosis and bronchiectasis

Research also addresses pulmonary arterial hypertension and interstitial lung diseases associated with systemic conditions. Clinical trials explore novel mechanisms of action and combination therapies to enhance treatment efficacy and patient outcomes in respiratory medicine.

05 Neurology and Neurodegenerative Diseases

Austrian clinical research includes studies on Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Trials assess disease-modifying therapies, symptomatic treatments, and interventions aimed at slowing cognitive decline and improving motor function in patients with neurodegenerative and neurological disorders.

  • Early Alzheimer's disease and mild cognitive impairment
  • Parkinson's disease and multiple system atrophy
  • Relapsing and progressive forms of multiple sclerosis
  • Huntington's disease and rare neurological conditions

Studies also investigate epilepsy, stroke, and neuromuscular disorders. Research efforts focus on developing new therapeutic strategies to address unmet medical needs and improve the quality of life for patients with chronic neurological conditions.

06 Metabolic and Endocrine Disorders

Clinical trials in Austria explore treatments for type 2 diabetes, obesity, and dyslipidemia. Research evaluates novel glucose-lowering agents, weight management therapies, and lipid-modifying drugs to reduce cardiovascular risk and improve metabolic health in patients with endocrine and metabolic disorders.

  • Type 2 diabetes mellitus and glycemic control
  • Obesity and overweight with cardiometabolic risk factors
  • Familial hypercholesterolemia and severe hypertriglyceridemia
  • Nonalcoholic steatohepatitis and metabolic liver disease

Studies also address acromegaly, Cushing syndrome, and congenital adrenal hyperplasia. Trials aim to optimize treatment regimens, improve patient adherence, and achieve better long-term outcomes in individuals with complex endocrine conditions.

07 Dermatology and Skin Disorders

Research in Austria includes trials on atopic dermatitis, psoriasis, and hidradenitis suppurativa. Studies evaluate topical and systemic therapies, including biologics and small molecules, to reduce skin inflammation, improve lesion clearance, and enhance quality of life for patients with chronic dermatological conditions.

  • Moderate to severe atopic dermatitis in adults and children
  • Plaque psoriasis and psoriatic arthritis
  • Hidradenitis suppurativa and prurigo nodularis
  • Rare skin conditions such as epidermolysis bullosa

Clinical trials also investigate vitiligo, bullous pemphigoid, and cutaneous lupus erythematosus. Research efforts focus on identifying effective treatments that control disease activity, prevent flares, and improve patient well-being in dermatology.

08 Nephrology and Kidney Diseases

Austrian research institutions conduct trials on chronic kidney disease, IgA nephropathy, and kidney transplantation. Studies evaluate therapies to slow disease progression, reduce proteinuria, and improve graft survival in patients with renal disorders and transplant recipients.

  • Chronic kidney disease and albuminuria
  • IgA nephropathy and glomerulonephritis
  • Antibody-mediated rejection in kidney transplant recipients
  • Polycystic kidney disease and hereditary renal conditions

Research also addresses delayed graft function and renal failure in patients with multiple myeloma. Clinical trials aim to develop interventions that preserve kidney function, improve patient outcomes, and reduce the burden of renal disease.

09 Gastroenterology and Hepatology

Clinical trials in Austria focus on inflammatory bowel disease, liver cirrhosis, and primary biliary cholangitis. Research evaluates novel therapies for Crohn's disease and ulcerative colitis, as well as treatments for chronic liver conditions to improve disease control and prevent complications.

  • Crohn's disease and ulcerative colitis with moderate to severe activity
  • Primary biliary cholangitis and primary sclerosing cholangitis
  • Nonalcoholic steatohepatitis and liver fibrosis
  • Acute-on-chronic liver failure and portal hypertension

Studies also investigate eosinophilic esophagitis, gastroparesis, and short bowel syndrome. Trials aim to identify effective interventions that reduce symptoms, improve nutritional status, and enhance quality of life for patients with gastrointestinal and hepatic disorders.

10 Ophthalmology and Vision Disorders

Austrian research includes trials on age-related macular degeneration, diabetic macular edema, and glaucoma. Studies evaluate intravitreal therapies, sustained-release devices, and novel agents to preserve vision, reduce disease progression, and improve visual outcomes in patients with retinal and optic nerve disorders.

  • Neovascular age-related macular degeneration
  • Diabetic macular edema and retinal vein occlusion
  • Geographic atrophy and dry macular degeneration
  • Retinitis pigmentosa and hereditary retinal diseases

Clinical trials also address uveitis, thyroid eye disease, and myopia. Research efforts focus on developing innovative treatments that protect vision, reduce inflammation, and improve quality of life for patients with chronic eye conditions.

11 Rare and Genetic Disorders

Austria participates in trials for rare diseases and genetic disorders, including Fabry disease, hemophilia, and hereditary angioedema. Studies evaluate enzyme replacement therapies, gene therapies, and novel agents to manage symptoms, prevent complications, and improve outcomes for patients with rare conditions.

  • Fabry disease and lysosomal storage disorders
  • Hemophilia A and B with or without inhibitors
  • Hereditary angioedema and complement-mediated diseases
  • Duchenne muscular dystrophy and neuromuscular disorders

Research also includes achondroplasia, Friedreich's ataxia, and epidermolysis bullosa. Clinical trials aim to develop targeted therapies that address the underlying causes of these conditions and improve patient quality of life.

12 Infectious Diseases and Immunodeficiency

Clinical trials in Austria investigate treatments for HIV infection, hepatitis D, and invasive fungal infections. Studies evaluate antiretroviral therapies, antiviral agents, and antifungal drugs to control infections, prevent disease progression, and reduce transmission in patients with infectious diseases.

  • HIV pre-exposure prophylaxis and treatment
  • Chronic hepatitis D virus infection
  • Invasive aspergillosis and candidemia
  • Tuberculosis and nontuberculous mycobacterial infections

Research also addresses COVID-19, respiratory syncytial virus, and secondary immunodeficiency. Trials aim to develop effective interventions that improve patient outcomes, reduce hospitalizations, and enhance public health responses to infectious threats.

13 Psychiatry and Mental Health

Austrian research includes trials on major depressive disorder, schizophrenia, and bipolar disorder. Studies evaluate antidepressants, antipsychotics, and mood stabilizers to improve symptom control, cognitive function, and quality of life in patients with psychiatric conditions.

  • Major depressive disorder and treatment-resistant depression
  • Schizophrenia and schizoaffective disorder
  • Bipolar disorder and mood stabilization
  • Obsessive-compulsive disorder and anxiety disorders

Clinical trials also investigate narcolepsy, delayed sleep-wake phase disorder, and anorexia nervosa. Research efforts focus on developing novel therapeutic approaches that address the complex neurobiological and psychological aspects of mental health disorders.

14 Pediatric and Neonatal Research

Austria conducts clinical trials in pediatric populations, addressing conditions such as acute lymphoblastic leukemia, juvenile idiopathic arthritis, and cystic fibrosis. Studies evaluate age-appropriate therapies to improve outcomes, reduce treatment-related toxicity, and support healthy development in children with chronic diseases.

  • Pediatric acute lymphoblastic leukemia and lymphomas
  • Juvenile idiopathic arthritis and autoimmune conditions
  • Cystic fibrosis and chronic respiratory diseases in children
  • Neonatal respiratory distress syndrome and prematurity complications

Research also includes growth hormone deficiency, congenital heart disease, and rare genetic disorders in children. Clinical trials aim to optimize treatment strategies, improve long-term health outcomes, and enhance quality of life for pediatric patients and their families.

15 Transplantation and Graft Management

Clinical trials in Austria focus on solid organ transplantation, including kidney, liver, and lung transplants. Studies evaluate immunosuppressive regimens, organ preservation techniques, and strategies to prevent graft rejection and improve long-term graft survival in transplant recipients.

  • Kidney transplantation and antibody-mediated rejection
  • Liver transplantation and delayed graft function
  • Lung transplantation and bronchiolitis obliterans syndrome
  • Graft-versus-host disease in hematopoietic stem cell transplant recipients

Research also addresses chronic graft-versus-host disease and immunosuppression optimization. Trials aim to develop interventions that enhance transplant outcomes, reduce complications, and improve quality of life for patients undergoing organ and stem cell transplantation.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.